7759.Two
7759.TWO operates in the healthcare sector, specifically within pharmaceuticals and medical research, focusing on biotechnology and medical research activities.
Business. 7759.TWO operates in the healthcare sector, specifically within pharmaceuticals and medical research, focusing on biotechnology and medical research activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
7759.TWO operates in the healthcare sector, specifically within pharmaceuticals and medical research, focusing on biotechnology and medical research activities.
The company maintains a strong liquidity position, with a current ratio of 16.48, indicating a significant ability to meet short-term obligations. The company's liquidity is further supported by a high cash and equivalents balance of TWD 354,720,000, which is a substantial portion of its total assets. However, the company's financial performance is weak, with a negative return on equity of -36.54% and a negative return on assets of -34.56%, suggesting poor profitability and asset utilization.
The company's profitability is a concern, as it reported a net loss of TWD -172,386,000 and an operating loss of TWD -176,329,000. These figures are significantly below the industry median for profitability metrics, indicating that the company is underperforming relative to its peers. The company's debt-to-equity ratio is very low at 0.01, suggesting minimal leverage and a conservative capital structure.
The company's revenue is reported as TWD 0.0, which indicates either a lack of disclosed revenue or a potential data issue. This lack of revenue data makes it difficult to assess the company's market position and growth potential. The company's operating cash flow is negative at TWD -144,892,000, and its free cash flow is also negative at TWD -167,056,000, indicating that the company is not generating sufficient cash from operations to sustain its activities.
The company's growth trajectory is unclear due to the lack of revenue data and the absence of a clear outlook for the current and next fiscal years. The company's capital expenditure is minimal at TWD -415,000, suggesting that it is not investing heavily in new projects or infrastructure. The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
Recent events and filings do not provide specific details about the company's operations or strategic direction. The company's financial statements do not include recent transcripts or detailed filings that could provide insight into its business strategy or operational performance.
- The company has a strong liquidity position with a high current ratio and significant cash reserves.
- The company is experiencing significant financial losses, with negative returns on equity and assets.
- The company's capital structure is conservative, with minimal debt and a high equity position.
- The company's growth and revenue generation are unclear due to the lack of disclosed revenue data.
- "margin_outlook_rationale": "The company's margin outlook is negative due to its significant operating and net losses.",
- "rd_outlook_rationale": "The company's R&D outlook is uncertain due to the lack of disclosed revenue and investment data.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 7759.TWO Market data — financials · 2026-05-27